Effects of cannabis and its components on the retina: a systematic review

References

• World Drug Report. New York: United Nations Office on Drugs and Crime; 2018. United Nations Publication Sales No. E.18.XI.9.
   Google Scholar
• Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacol 2018;43:195–212.
   PubMed Web of Science ®Google Scholar
• Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology 2016;151:252–266.
   PubMed Web of Science ®Google Scholar
• Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 2018;19:e833.
   PubMed Web of Science ®Google Scholar
• Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav 2017;70:319–327.
   PubMed Web of Science ®Google Scholar
• Skaper SD, Marzo VD. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Phil Trans R Soc B 2012;367:3193–3200.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Yarnell S, Radhakrishnan R, et al. Marijuana legalization: impact on physicians and public health. Annu Rev Med 2016;67:453–466.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med 2009;6:1–6.
   Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012.
   PubMed Web of Science ®Google Scholar
• OHAT (Office of Health Assessment and Translation). Handbook for conducting a literature-based health assessment using OHAT approach for systematic review and evidence integration. Office of Health Assessment and Translation. Research Triangle Park, NC: Division of the National Toxicology Program. National Institute of Environmental Health Sciences; 2015.
   Google Scholar
• Pérez JG, Mato PM, Garcia SA, Rey D. Intraocular motility, electrophysiological tests and visual fields in drug addicts. Ophthal Physiol Opt 1995;15:493–498.
   PubMed Web of Science ®Google Scholar
• Aktaș S, Tetikoğlu M, İnan S, et al. Unilateral hemorrhagic macular infarction associated with marijuana, alcohol and antiepileptic drug intake. Cutan Ocul Toxicol 2017;36:88–95.
   PubMed Web of Science ®Google Scholar
• Corvi F, Querques G, Lattanzio R, et al. Central retinal vein occlusion in a young patient following cannabis smoke inhalation. Eur J Ophthalmol 2014;24:437–440.
   PubMed Web of Science ®Google Scholar
• Plange N, Arend KO, Kaup M, et al. Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 2007;143:173–174.
   PubMed Web of Science ®Google Scholar
• MacIntyre J, Dong A, Straiker A, et al. Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. Eur J Pharmacol 2014;735:105–114.
   PubMed Web of Science ®Google Scholar
• Su E, Kelly ME, Cringle SJ, Yu D. Role of endothelium in abnormal cannabidiol-induced vasoactivity in retinal arterioles. Invest Ophthalmol Vis Sci 2015;56:4029–4037.
   PubMed Web of Science ®Google Scholar
• Liu HF, He Y, Jia J, et al. Clinical study on intravitreal injection of cannabinoid HU – 211 for optic nerve damage in glaucoma rats. Int Eye Sci 2014;14:1584–1586.
   Google Scholar
• Crandall J, Matragoon S, Khalifa YM, et al. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic Res 2007;39:69–75.
   PubMed Web of Science ®Google Scholar
• El-Remessy AB, Tang Y, Zhu G, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis 2008;14:2190–2203.
   PubMed Web of Science ®Google Scholar
• Faure C, Schwitzer T, Hansen C, Randhawa S. Diagnostic and therapeutic challenges. Retina 2016;36:2433–2439.
   PubMedGoogle Scholar
• Russo EB, Merzouki A, Mesa JM, et al. Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco. J Ethnopharmacol 2004;93:99–104.
   PubMed Web of Science ®Google Scholar
• Schwitzer T, Robert MP, Giersch A, et al. Transient retinal dysfunctions after acute cannabis use. Eur Addict Res 2016;22:287–291.
   PubMed Web of Science ®Google Scholar
• Schwitzer T, Schwan R, Albuisson E, et al. Association between regular cannabis use and ganglion cell dysfunction. JAMA Ophthalmol 2017;135:54–60.
   PubMed Web of Science ®Google Scholar
• Zobor D, Strasser T, Zobor G, et al. Ophthalmological assessment of cannabis-induced persisting perception disorder: is there a direct retinal effect? Doc Ophthalmol 2015;130:121–130.
   PubMed Web of Science ®Google Scholar
• Onur OS, Sena K, Onur IU, Karsidag C. Evaluation of the effects of synthetic cannabinoids (Bonzai) on choroid and retina. Eur Neuropsychopharmacol 2016;26:S704.
   Web of Science ®Google Scholar
• Hamilton R, McGlone L, MacKinnon JR, et al. Ophthalmic, clinical and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy. Br J Ophthalmol 2010;94:696–700.
   PubMed Web of Science ®Google Scholar
• Stanley C, O’Sullivan E. Vascular targets for cannabinoids: animal and human studies. Br J Pharmacol 2014;171:1361–1378.
   PubMed Web of Science ®Google Scholar
• Ashton JC, Smith PF. Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol 2007;5:175–184.
   PubMed Web of Science ®Google Scholar
• Chen Y, Luo X, Liu S, Shen Y. Neuroprotective effect of cannabinoid receptor 1 antagonist in the MNU-induced retinal degeneration model. Ex Eye Res 2018;167:145–151.
   PubMed Web of Science ®Google Scholar
• Gado F, Digiacomo M, Macchia M, et al. Traditional uses of cannabinoids and new perspectives in the treatment of multiple sclerosis. Medicines 2018;5:E91.
   Google Scholar
• Petrosino S, Verde R, Vaia M, et al. Anti-inflammatory properties of cannabidiol, a non-psychotropic cannabinoid, in experimental allergic contact dermatitis. J Pharmacol Exp Ther 2018;365:652–663.
   PubMed Web of Science ®Google Scholar
• Klein M, Bortolli JQ, Guimarães FS, et al. Effects of cannabidiol, a Cannabis sativa constituent, on oral wound healing process in rats: clinical and histological evaluation. Phytother Res 2018;32:2275–2281.
   PubMed Web of Science ®Google Scholar
• Norooznezhad AH, Norooznezhad F. Cannabinoids: possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Med Hypotheses 2017;99:15–18.
   PubMed Web of Science ®Google Scholar
• Ambrose T, Simmons A. Cannabis, cannabinoids and the endocannabinoid system - is there therapeutic potential for inflammatory bowel disease? J Crohns Colitis 2019;12:525–535.
   Google Scholar
• Milando R, Friedman A. Cannabinoids: potential role in inflammatory and neoplasic skin diseases. Am J Clin Dermatol 2018;20:167–180.
   Web of Science ®Google Scholar
• Martin JH, Schneider J, Lucas CJ, Galettis P. Exogenous cannabinoid efficacy: merely a pharmacokinetic interaction? Clin Pharmacokinet 2018;57:539–545.
   PubMed Web of Science ®Google Scholar
• Bassi MS, Sancesario A, Morace R, et al. Cannabinoids in Parkinson`s disease. Cannabis and Cannabinoid Res 2017;2:21–29.
   PubMedGoogle Scholar